LumiraDx Partners with British In Vitro Diagnostics


LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Today, LumiraDx Limited (Nasdaq: LMDX) a next-generation level of care diagnostics firm, in partnership the British In Vitro Diagnostics Association, launched the Testing Times report which outlines the function of speedy diagnostics in tackling antimicrobial resistance (AMR) and identifies limitations to their uptake in main and group care.

For sufferers presenting with signs of respiratory tract infections in main care, antibiotics are continuously prescribed with no willpower of whether or not the affected person has a bacterial an infection that may be handled by antibiotics. This is regardless of the supply of revealed proof on the worth of speedy testing for C-Reactive protein that has been proven to considerably scale back the prescribing of antibiotics, in keeping with a report launched as we speak.

“As we move forward from the pressures and challenges placed on the NHS by COVID-19, it’s critical that the UK government is looking to the future and the approaching crisis of AMR,” says Doris-Ann Williams, CEO of the British In Vitro Diagnostic Association. “Rapid diagnostics have a key role to play in community and primary care settings to lower unnecessary antibiotic prescribing, particularly in respiratory tract infections, and protect the healthcare system in the decades to come.”

To inform the report, healthcare professionals, lecturers and Government advisors on AMR shared their insights into coverage and frontline challenges in a collection of interviews led by Professor Jonathan Cooke, visiting Professor on the NIHR London In Vitro Diagnostics Co-operative, Department of Surgery and Cancer, Faculty of Medicine at Imperial College London and Honorary Professor within the Faculty of Biology, Medicine and Health, University of Manchester.

See also  Ozop Energy Solutions, Inc. Announces Completion of Initial

Point of care CRP testing reduces antibiotic prescribing by 22-36% for respiratory tract infections (RTI),1 and 22% for COPD.2 It is likely one of the only instruments there’s towards the main reason behind antimicrobial resistance: pointless antibiotic prescribing in main care. 

The Government’s 5 Year Action Plan on Antimicrobial Resistance: 2019-2024, concluded that the UK doesn’t make the very best use of obtainable diagnostic expertise.3 The British In Vitro Diagnostics Association and LumiraDx are calling on the NHS, Department of Health and Social Care and NICE to unlock the potential of level of care CRP testing to stop antimicrobial resistance. 

Key suggestions:

  • The Department of Health and Social Care and NHS England ought to contemplate decreasing NHS pressures by offering speedy diagnostics in new respiratory evaluation hubs and pharmacies.
  • NICE ought to revise its evaluation of diagnostic checks to incorporate strong financial modelling of the influence of AMR to find out the cost-effectiveness of utilizing speedy diagnostics.
  • New Integrated Care Systems ought to leverage economies of scale and have to be offered with applicable funding preparations and incentives to utilise speedy diagnostics in main and group care.

According to Professor Cooke, “The threat of AMR requires urgent attention and action on the part of the UK government. We’ve heard from experts and stakeholders across the board that challenges and barriers remain when looking to implement rapid point of care testing that can significantly reduce unnecessary antibiotic prescribing. Adopting systems that markedly reduce antibiotic consumption is critical for governments that are committed to addressing the rise in AMR.”

See also  Overland Park Regional Medical Center Extends Leadership in

Globally, it’s estimated that there are no less than 700,000 deaths per 12 months because of antimicrobial resistant an infection and that is anticipated to rise to 10 million deaths by 2050 if motion isn’t taken.4

The Testing Times Report could also be considered right here.

About LumiraDx and the LumiraDx CRP Test

Available on the LumiraDx Platform, the LumiraDx CRP Test is a quantitative, speedy POC take a look at to be used with direct fingerstick, venous entire blood and venous plasma samples, offering a willpower of C-Reactive Protein in simply 4 minutes. Test outcomes can assist help an knowledgeable choice about antibiotic prescribing within the area of the primary appointment.

LumiraDx Limited (Nasdaq: LMDX) is a next-generation level of care diagnostics firm that’s reworking community-based healthcare. Its actively managed microfluidic expertise supplies quick, excessive efficiency and accessible diagnostic options wherever the affected person is for almost any testing situation, creating distinctive testing choices on the level of want. 

The firm provides a broad menu of lab comparable checks on a single moveable Platform, with greater than 30 assays in the marketplace or within the pipeline, protecting infectious ailments, cardiovascular ailments, diabetes, and coagulation problems. The firm additionally helps high-complexity laboratory testing in an accessible high-throughput format to leverage present molecular laboratory operations.

Founded in 2014 and primarily based within the UK, LumiraDx’s diagnostic testing options are being deployed globally by governments and main healthcare establishments throughout laboratories, pressing care, doctor workplaces, pharmacies, colleges, and workplaces to display screen, assist in prognosis, and monitor wellness in addition to illness.
More data on LumiraDx is obtainable at



The British In Vitro Diagnostic Association (the IVD applied sciences business physique) is the go-to organisation supporting members to supply price efficient affected person outcomes utilizing IVD applied sciences and innovation to remodel affected person pathways.


1. Cooke J, Llor C, Hopstaken R, Dryden M, Butler C. Respiratory tract infections (RTIs) in main care: narrative evaluation of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in sufferers who current with signs of RTI. BMJ Open Respir Res. 2020;7(1):e000624. doi:10.1136/bmjresp-2020-000624 

2. Butler CC, Gillespie D, White P, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N Engl J Med. 2019;381(2):111-120. doi:10.1056/NEJMoa1803185 

3. Department of Health and Social Care. UK 5-year motion plan for antimicrobial resistance 2019-2024. January 2019. Available:

4. The Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. May 2016. Available:

Media Contact:

Source link


Please enter your comment!
Please enter your name here